Mutations of RAS/RAF proto-oncogenes impair survival after cytoreductive surgery and HIPEC for peritoneal metastasis of colorectal origin
MA Schneider, J Eden, B Pache, F Laminger… - Annals of …, 2018 - journals.lww.com
Background: Adequate selection of patients with peritoneal metastasis (PM) for
cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) …
cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) …
RAS Mutation Decreases Overall Survival After Optimal Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy of Colorectal Peritoneal Metastasis: A …
A Arjona-Sanchez, L Rodriguez-Ortiz, D Baratti… - Annals of surgical …, 2019 - Springer
Background Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy
(HIPEC) are currently the most accepted treatment for peritoneal metastases from colorectal …
(HIPEC) are currently the most accepted treatment for peritoneal metastases from colorectal …
Microsatellite and RAS/RAF mutational status as prognostic factors in colorectal peritoneal metastases treated with cytoreductive surgery and hyperthermic …
M Tonello, D Baratti, P Sammartino… - Annals of surgical …, 2022 - Springer
Background Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy
(HIPEC) leads to prolonged survival for selected patients with colorectal (CRC) peritoneal …
(HIPEC) leads to prolonged survival for selected patients with colorectal (CRC) peritoneal …
[HTML][HTML] Prognostic Impact of BRAF and KRAS Mutation in Patients with Colorectal and Appendiceal Peritoneal Metastases Scheduled for CRS and HIPEC
W Graf, PH Cashin, L Ghanipour, M Enblad… - Annals of Surgical …, 2020 - Springer
Background KRAS and BRAF mutations are prognostic and predictive tools in metastatic
colorectal cancer, but little is known about their prognostic value in patients scheduled for …
colorectal cancer, but little is known about their prognostic value in patients scheduled for …
Predictors of survival in patients with high-grade peritoneal metastases undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
HL Van Sweringen, DJ Hanseman, SA Ahmad… - Surgery, 2012 - Elsevier
BACKGROUND: Peritoneal metastases in patients with high-grade adenocarcinoma have
been typically associated with a poor outcome. Recent literature has suggested that …
been typically associated with a poor outcome. Recent literature has suggested that …
Complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastasis in Norway: prognostic factors and oncologic …
IS Frøysnes, SG Larsen, M Spasojevic… - Journal of surgical …, 2016 - Wiley Online Library
Background and Objectives Cytoreductive surgery (CRS) and hyperthermic intraperitoneal
chemotherapy (HIPEC) can offer long‐term survival to patients with resectable peritoneal …
chemotherapy (HIPEC) can offer long‐term survival to patients with resectable peritoneal …
Patient selection for cytoreductive surgery and HIPEC for the treatment of peritoneal metastases from colorectal cancer
GA Simkens, KP Rovers, SW Nienhuijs… - Cancer management …, 2017 - Taylor & Francis
Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) is a
viable option for selected patients with peritoneal metastases (PM) from colorectal origin …
viable option for selected patients with peritoneal metastases (PM) from colorectal origin …
[HTML][HTML] Challenging the dogma of colorectal peritoneal metastases as an untreatable condition: results of a population-based study
LGEM Razenberg, VEPP Lemmens, VJ Verwaal… - European Journal of …, 2016 - Elsevier
Purpose To determine the impact of the implementation of novel systemic regimens and
locoregional treatment modalities on survival at population level in colorectal cancer (CRC) …
locoregional treatment modalities on survival at population level in colorectal cancer (CRC) …
Cytoreductive surgery and hyperthermic intra‐peritoneal chemotherapy treatment of colorectal peritoneal metastases: Cohort analysis of high volume disease and …
PH Cashin, F Dranichnikov… - Journal of surgical …, 2014 - Wiley Online Library
Background Cytoreductive surgery (CRS) and hyperthermic intra‐peritoneal chemotherapy
(HIPEC) treatment of colorectal peritoneal metastases (PM) is an established treatment …
(HIPEC) treatment of colorectal peritoneal metastases (PM) is an established treatment …
[HTML][HTML] Impact of KRAS, BRAF and microsatellite instability status after cytoreductive surgery and HIPEC in a national cohort of colorectal peritoneal metastasis …
SG Larsen, MA Goscinski, S Dueland… - British journal of …, 2022 - nature.com
Background Patients with metastatic colorectal cancer (mCRC) carrying BRAF (mut BRAF)
or KRAS mutation (mut KRAS) have an inferior prognosis after liver or lung surgery, whereas …
or KRAS mutation (mut KRAS) have an inferior prognosis after liver or lung surgery, whereas …
相关搜索
- peritoneal metastases cytoreductive surgery
- colorectal cancer cytoreductive surgery
- peritoneal metastasis colorectal origin
- peritoneal metastasis proto oncogenes
- proto oncogenes cytoreductive surgery
- proto oncogenes colorectal origin
- survival in patients cytoreductive surgery
- crs and hipec kras mutation
- hipec for the treatment cytoreductive surgery
- hyperthermic intra cytoreductive surgery
- prognostic factors cytoreductive surgery
- hipec for the treatment colorectal cancer
- hipec for the treatment peritoneal metastases
- peritoneal metastases kras mutation
- impact of kras cytoreductive surgery
- mutational status cytoreductive surgery